Agilon Health (AGL) Returns To Profit On A Valuation That Still Looks Undemanding
What the latest earnings reveal about agilon health
agilon health (AGL) flipped to profit in the third quarter of 2026, reporting US$1,519.49 million in revenue and net income of US$34.91 million after a sizeable loss a year earlier.
Over the first nine months of 2026, the business reported US$4,434.69 million in revenue and net income of US$101.78 million. This gives investors fresh detail on how its model for senior-focused primary care is translating into earnings.
agilon health’s latest results landed alongside a sharp swing in sentiment, with the share price up 9.61% over one day, delivering a 14.18% 30 day share price return and a very large year to date gain that contrasts with a 5 year total shareholder return decline of 84.79%.
The recent jump in the stock price, including a 10.83% 90 day share price return and a 410.84% 1 year total shareholder return, points to investors reassessing both the earnings turnaround and the risks that had previously weighed on the company.
Compare agilon health's sharp swing back to profit with a curated set of healthcare peers, screened for strong balance sheets and fundamentals in the list of solid balance sheet and fundamentals (25 results).
The swing in agilon health’s share price and earnings tempts some investors to jump in now, while others prefer to wait for a calmer entry. So what does the current valuation actually suggest about that trade off?
Most Popular agilon health Narrative: 17% Undervalued
On the most followed valuation view, agilon health is priced below an implied fair value of $115.83, compared with the latest close at $96.23. That gap reflects a thesis that the senior-focused model is shifting from growth at all costs to more disciplined risk-taking and earnings quality.
The current valuation implies the market is already pricing in meaningful success for agilon health in translating higher revenue guidance, stronger medical margin and ACO savings into a more profitable and durable full-risk senior care model.
See why 11 investors see agilon health as 17% undervalued.
Result: Fair Value of $115.83 (UNDERVALUED)
Still, declining Medicare Advantage membership, along with reports of weak customer growth and cash burn, could challenge the agilon health turnaround story that investors are currently focused on.
Find out about the key risks to this agilon health narrative.
Next Steps
Mixed signals on agilon health so far. If the combination of improving profit and lingering questions has you on the fence, consider reviewing the data yourself, starting with the 3 key rewards and 1 important warning sign.
Looking for more agilon health style investment ideas?
Do not stop with agilon health. Use the Simply Wall St Screener to uncover fresh opportunities that match your risk profile and return expectations before the crowd spots them.
- Target potential mispricing by scanning a curated universe of high quality companies using the 34 high quality undervalued stocks.
- Prioritise resilience and capital preservation by focusing on businesses that show stronger risk profiles in the 31 resilient stocks with low risk scores.
- Hunt for underfollowed opportunities with solid fundamentals that the market may be overlooking through the 19 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com